ASX Announcements

Name: Amplia Therapeutics
Address: Level 29, 55 Collins Street, Melbourne, VIC, 3000, Australia

29-Sep-2023	AACR Pancreatic Cancer Conference Presentation

25-Sep-2023	New Chief Financial Officer Mr Tim Luscombe

4-Sep-2023	Notification of cessation of securities - ATX

1-Sep-2023	Notification of cessation of securities - ATX

1-Sep-2023	Change of Director's Interest Notice - Dr Robert Peach

29-Aug-2023	Change of Director's Interest Notice - Dr Christopher Burns

29-Aug-2023	Notification regarding unquoted securities - ATX

24-Aug-2023	Results of Annual General Meeting

24-Aug-2023	CEO and MD Presentation to Annual General Meeting

2-Aug-2023	ACCENT Trial Recruitment Update

31-Jul-2023	ATX Quarterly Activities and Cashflow Reports - June 23 Qtr

21-Jul-2023	Notice of Annual General Meeting/Proxy Form

20-Jul-2023	ATX - Shareholder Newsletter July 2023

12-Jul-2023	Application for quotation of securities - ATX

21-Jun-2023	AMP945 International Nonproprietary Name Narmafotinib

19-Jun-2023	Amplia AGM to be held Thursday 24 August 2023

31-May-2023	Key to Corporate Governance Disclosures

30-May-2023	2023 Corporate Governance Statement

30-May-2023	Annual Report to Shareholders

29-May-2023	AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

23-May-2023	Grant to collaborate with CSIRO Supplementary Announcement

22-May-2023	Amplia receives grant to collaborate with CSIRO

9-May-2023	ACCENT Trial Recruitment Progress

26-Apr-2023	Quarterly Activities and Cashflow Reports - March 23 Qtr

19-Apr-2023	First Patient Recruited to Cohort 3 of ACCENT Trial

11-Apr-2023	Dose Escalation Approved in ACCENT Clinical Trial of AMP945

28-Feb-2023	ACCENT Trial Recruitment Progress

23-Feb-2023	ATX - US Conference Presentation

9-Feb-2023	AmpliaTherapeutics - Lorne Cancer Conference Presentation

1-Feb-2023	First Patient Recruited to Cohort 2 of Accent Trial

30-Jan-2023	Quarterly Activities and Cashflow Reports - December 2022

11-Jan-2023	Dose Escalation Approved in ACCENT Clinical Trial of AMP945

20-Dec-2022	Letter to Shareholders End of Year Summary and 2023 Plans

1-Dec-2022	Final Director's Interest Notice - Dr. John Lambert

29-Nov-2022	ACCENT Trial Recruitment Progress

18-Nov-2022	Appendix 4D and Financial Report Half Year ended 30 Sep 22

7-Nov-2022	Amplia Appoints Dr Christopher Burns CEO & Managing Director

28-Oct-2022	Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

10-Oct-2022	Notification regarding unquoted securities - ATX

3-Oct-2022	AMP886 Activity in Acute Myeloid Leukemia

14-Sep-2022	AACR Conference Presentation

12-Sep-2022	CEO Resignation

7-Sep-2022	Notification regarding unquoted securities - ATX

7-Sep-2022	Change of Director's Interest Notice - Dr. Warwick Tong

7-Sep-2022	Change of Director's Interest Notice - Dr. Robert Peach

7-Sep-2022	Change of Director's Interest Notice - Dr. Christopher Burns

7-Sep-2022	Change of Director's Interest Notice - Mrs. Jane Bell

6-Sep-2022	Change of Director's Interest Notice - Dr. John Lambert

2-Sep-2022	Notification of cessation of securities - ATX

31-Aug-2022	Amplia Receives $1.8m R&D Tax Incentive

25-Aug-2022	Results of Annual General Meeting

25-Aug-2022	CEO & Managing Director Presentation to AGM

17-Aug-2022	Annual General Meeting - ESOP and New Constitution

17-Aug-2022	Employee Security Ownership Plan

4-Aug-2022	Change of Director's Interest Notice - Dr. Warwick Tong

2-Aug-2022	First Patient Recruited to ACCENT Trial in Pancreatic Cancer

28-Jul-2022	Quarterly Activities and Cashflow Reports - June 2022 Qtr

25-Jul-2022	Presentation at Major Pancreatic Cancer Conference

22-Jul-2022	Notice of Annual General Meeting/Proxy - YE 31 March 2022

7-Jul-2022	Change of Director's Interest Notice - Dr. Chistopher Burns

7-Jul-2022	Change of Director's Interest Notice - Dr. Robert Peach

7-Jul-2022	Change of Director's Interest Notice - Dr. John Lambert

7-Jul-2022	Change of Director's Interest Notice - Dr. Warwick Tong

5-Jul-2022	Notification of cessation of securities - ATX

30-Jun-2022	Application for quotation of securities - ATX

29-Jun-2022	Annual General Meeting to be held Thursday 25 August 2022

24-Jun-2022	Registered Office and Principal Place of Business

9-Jun-2022	Notification of Expiry of Unlisted Options

9-Jun-2022	Application for quotation of securities - ATX

2-Jun-2022	AMP945 Shows Efficacy in Model of Lung Fibrosis

30-May-2022	App 4G - Key to Corporate Governance Disclosures

30-May-2022	Corporate Governance Statement

30-May-2022	Preliminary Final Report and Annual Report YE 31 March 2022

13-May-2022	Amplia Receives Second Ethics Clearance for Phase 2 Trial

12-May-2022	Amplia Presentation to 16th Bioshares Biotech Summit

9-May-2022	AMP945 Pre-IND Meeting Outcome

19-Apr-2022	Quarterly Activities and Cashflow Reports - March 2022 Qtr

6-Apr-2022	Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients

5-Apr-2022	Notification of cessation of securities - ATX

17-Feb-2022	AMP945 Improves Survival in Human Pancreatic Cancer Model

15-Feb-2022	ATX Abstract accepted for presentation at Cancer Conference

14-Feb-2022	Sale of Unmarketable Parcels of Shares

10-Feb-2022	Change of Director's Interest Notice - Jane Bell

1-Feb-2022	Amplia Investor Presentation - February 2022

24-Jan-2022	Quarterly Activities and Cashflow Reports - Dec 2021 Qtr

19-Jan-2022	Notification regarding unquoted securities - ATX

13-Jan-2022	Amplia Completes Manufacture of AMP945 for Planned Trials

22-Dec-2021	Application for quotation of securities - ATX

22-Dec-2021	Application for quotation of securities - ATX

21-Dec-2021	App 3Y - Change of Director's Interest - Mrs Jane Bell

21-Dec-2021	App 3Y - Change of Director's Interest - Dr. Chris Burns

21-Dec-2021	App 3Y - Change of Director's Interest - Dr. Robert Peach

21-Dec-2021	App 3Y - Change of Director's Interest - Dr. John Lambert

21-Dec-2021	App 3Y - Change of Directors Interest Notice - Dr. W. Tong

21-Dec-2021	Proposed issue of securities - ATX

20-Dec-2021	Update - Application for quotation of securities - ATX

17-Dec-2021	Results of Extraordinary General Meeting

16-Dec-2021	Amplia Provides Updated Investor Presentation

15-Dec-2021	Update - Application for quotation of securities - ATX

14-Dec-2021	Update - Proposed issue of securities - ATX

10-Dec-2021	Entitlement Offer Completed

2-Dec-2021	Amplia Awarded $2.1M R&D Cash Flow Loan

24-Nov-2021	App 4D and Financial Report Half Year ended 30 Sep 2021

19-Nov-2021	Notice of Extraordinary General Meeting - 17 Dec 2021

18-Nov-2021	Summary Results - Successful Phase 1 Clinical Trial AMP945

17-Nov-2021	Inhibition of FAK by AMP945 in Phase 1 Clinical Trial

16-Nov-2021	Becoming a Substantial Holder - Acorn Capital Limited

15-Nov-2021	Application for quotation of securities - ATX

15-Nov-2021	Change in substantial holding

15-Nov-2021	Application for quotation of securities - ATX

12-Nov-2021	Section 708A Cleansing Notice - Share Placement

12-Nov-2021	Blueflag Holding - Change of Interest of Substantial Holder

12-Nov-2021	Application for quotation of securities - ATX

8-Nov-2021	Proposed issue of securities - ATX

8-Nov-2021	Proposed issue of securities - ATX

8-Nov-2021	Capital Raising Investor Presentation

8-Nov-2021	Entitlement Offer Prospectus

8-Nov-2021	Placement and Underwritten Entitlement Offer to Raise $12.4m

4-Nov-2021	Amplia and CRUK agree to Amend Licence Terms - AMP886

4-Nov-2021	Trading Halt

27-Oct-2021	Quarterly Activities and Cashflow Reports - Sep 2021 Qtr

26-Oct-2021	Amplia Appoints New Oncology Clinical Advisor

19-Oct-2021	Amplia Provides Updated Investor Presentation

14-Oct-2021	Amplia Receives $1.1m R&D Tax Incentive

1-Oct-2021	Amplia Appoints New Chief Financial Officer

30-Sep-2021	New Garvan Publication Supports Amplia Phase 2 Design

28-Sep-2021	Proactive Investors Lifesciences Webinar Presentation

27-Sep-2021	Amplia to Present at Proactive Investor Lifesciences Webinar

15-Sep-2021	Phase 2 Trial in First-Line Pancreatic Cancer Patients

15-Sep-2021	Updated Investor Presentation

6-Sep-2021	Change of Director's Interest Notice - Jane Bell

27-Aug-2021	Results of Annual General Meeting

27-Aug-2021	AGM - Chief Executive Officer's Presentation

20-Aug-2021	Annual General Meeting Arrangements

28-Jul-2021	Quarterly Activities and Cashflow Reports and Presentation

26-Jul-2021	Shareholder Update and Presentation

23-Jul-2021	App 4G - Key to Corporate Governance Disclosures

23-Jul-2021	2021 Corporate Governance Statement

23-Jul-2021	Annual Report to Shareholders - YE 31 March 2021

23-Jul-2021	Notice of Annual General Meeting/Proxy Form

21-Jul-2021	Results from Successful Phase 1 Clinical Trial of AMP945

29-Jun-2021	Financial Report YE 31 March 2021 - Audited

28-Jun-2021	Amplia and Garvan Enter Into Collaboration Agreement

25-Jun-2021	Annual General Meeting to be Held 27 August 2021

8-Jun-2021	Change of Director's Interest - Dr. Lambert Exercise Options

7-Jun-2021	Application for quotation of securities - ATX

7-Jun-2021	Application for quotation of securities - ATX

2-Jun-2021	AMP945 Improves Survival in Pancreatic Cancer Model

1-Jun-2021	Application for Quotation of Shares - Options Exercised

31-May-2021	App 4E - Preliminary Final Report YE 31 March 2021

11-May-2021	Change in substantial holding

10-May-2021	Section 708A Cleansing Notice - Share Placement

10-May-2021	Appendix 2A - Application for Quotation of Shares

10-May-2021	Appendix 3G - Notification of Issue of Securties - Options

4-May-2021	Proposed issue of Securities - ATX

4-May-2021	Amplia Announces $3.8m Share Placement

30-Apr-2021	Trading Halt

28-Apr-2021	Preclinical Data Support Development AMP945 Pancreatic Cancer

28-Apr-2021	Quarterly Report and Shareholder Update

22-Apr-2021	Initial Director's Interest Notice - Jane Bell

22-Apr-2021	Shareholder Update and Presentation

20-Apr-2021	ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH

15-Apr-2021	Amplia Completes Dosing in Phase 1 Clinical Study of AMP945

12-Apr-2021	Amplia Appoints New Non-Executive Director

25-Mar-2021	Change of Registered Office and Principal Place of Business

24-Mar-2021	Appendix 2A - Exercise of Options

18-Mar-2021	Amplia and Garvan Institute Enter Collaboration Agreement

17-Mar-2021	Amplia Completes Single Dose Study of AMP945

17-Feb-2021	Amplia Initiates Multiple Dose Study of AMP945

16-Feb-2021	Appendix 2A - Exercise of Options

11-Feb-2021	Investor Update - February 2021

28-Jan-2021	Quarterly Activities and Cashflow Reports - Dec 2020 Qtr

11-Jan-2021	Appendix 2A - Exercise of Options

17-Dec-2020	Shareholder Update - 2020 Review

2-Dec-2020	Amplia Receives $0.53m R&D Tax Incentive

27-Nov-2020	Appendix 4D and Financial Report Half Year Ended 30 Sep 2020

24-Nov-2020	Appendix 2A - Allot Shares upon Exercise of Options

2-Nov-2020	Notice ASX LR 3.11.2 - Change of Exercise Price of Options

29-Oct-2020	ATX - Sep 2020 Quarter Activities and Cashflow Reports

21-Oct-2020	Amplia Presentation to Reach Market Services - Meet the CEO

20-Oct-2020	Response to ASX Price Query

8-Oct-2020	First Human Dose in Phase 1 Clinical Trial of AMP945

18-Sep-2020	Change of Director's Interest Notice - Dr. Warwick Tong

18-Sep-2020	Change of Director's Interest Notice - Dr. Robert Peach

18-Sep-2020	Change of Director's Interest Notice - Dr. C. Burns

18-Sep-2020	Section 708A Cleansing Notice - Allotment of Shares

18-Sep-2020	Appendix 2A - Application for Quotation of Shares

18-Sep-2020	Results of Annual General Meeting

18-Sep-2020	CEO Presentation to AGM

8-Sep-2020	Amplia Receives Ethics Clearance to Conduct Phase 1 Trial

2-Sep-2020	Appendix 3G - Notification of Issue of Securities - Options

31-Aug-2020	Amplia Appoints Dr Mark Devlin as Chief Scientific Officer

17-Aug-2020	Notice of Annual General Meeting & Proxy - YE 31 March 2020

6-Aug-2020	Change in Substantial Holding - Blueflag Holdings Pty Ltd

6-Aug-2020	Change in Substantial Holding - Platinum Investment Management Limited

5-Aug-2020	Change of Director Interest - Dr Lambert - Entitlement Offer

5-Aug-2020	Change of Directors Interest - Dr W Tong - Entitlement Offer

4-Aug-2020	Appendix 2A - Retail Entitlement Offer

31-Jul-2020	Appendix 4G - Key to Corporate Governance Disclosures

31-Jul-2020	2020 Corporate Governance Statement

31-Jul-2020	Annual Report to Shareholders - YE 31 March 2020

30-Jul-2020	Entitlement Offer Completed

27-Jul-2020	Quarterly Activities and Cashflow Reports - June 2020

23-Jul-2020	Nucleus Network Appointed to Conduct Phase 1 Clinical Trial

20-Jul-2020	AGM to be held Friday 18 September 2020

14-Jul-2020	Change of Director's Interest Notice - Dr. Warwick Tong

14-Jul-2020	Becoming a substantial holder

14-Jul-2020	Becoming a substantial holder

14-Jul-2020	Change in substantial holding

10-Jul-2020	Appendix 2A - Institutional Entitlement Offer

8-Jul-2020	Entitlement Offer - Despatch of Retail Offer Booklet

3-Jul-2020	Institutional Entitlement Offer Completed

1-Jul-2020	Appendix 3B - Rights Issue

1-Jul-2020	Entitlement Offer Cleansing Notice

1-Jul-2020	Capital Raising - Investor Presentation

1-Jul-2020	Entitlement Offer to Fund Phase 1 Clinical Trial

30-Jun-2020	Preclinical Toxicology Studies Support Phase1 Clinical Trial

29-Jun-2020	Trading Halt

25-Jun-2020	Full Year Statutory Accounts - YE 31 March 2020

2-Jun-2020	Investor Presentation

29-May-2020	Preliminary Final Report - YE 31 March 2020

19-May-2020	FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis

28-Apr-2020	Quarterly Activities Report - March 2020 Qtr

28-Apr-2020	App 4C - Quarterly Cash Flow Report - March 2020 Qtr

7-Apr-2020	Shares to be Released from Voluntary Escrow

25-Mar-2020	FDA Awards Orphan Drug Designation for Pancreatic Cancer

13-Feb-2020	Professor Paul Timpson Joins Amplia's SAB

12-Feb-2020	Initial Director's Interest Notice - John Lambert

7-Feb-2020	Final Director's Interest Notice - Behrenbruch

7-Feb-2020	Final Director's Interest Notice - Wilkinson

7-Feb-2020	Final Director's Interest Notice - Cooke

6-Feb-2020	Dr. John Lambert appointed as Managing Director

6-Feb-2020	Board Restructuring

30-Jan-2020	Placement Cleasing Statement

30-Jan-2020	Appendix 4C Cash Flow - Dec 2019 Qtr

28-Jan-2020	Ceasing to be a substantial holder - Behrenbruch

28-Jan-2020	Becoming a substantial holder

24-Jan-2020	Appendix 3B - Placement

20-Jan-2020	Amplia Therapeutics Undertakes Placement

16-Jan-2020	Trading Halt

18-Dec-2019	Change of Registered Office and Principal Place of Business

17-Dec-2019	Shareholder Update / 2019 Review

29-Nov-2019	App 4D - Financial Report Half Year Ended 30 Sep 2019

1-Nov-2019	App 4C - Sep 2019 Qtr Cash Flows Statement

17-Sep-2019	Change of Director's Interest - Dr Robert Peach - Placement

17-Sep-2019	Change of Director's Interest - Dr C Behrenbruch - Placement

17-Sep-2019	Change of Director's Interest - Dr Warwick Tong, Placement

17-Sep-2019	Placement Cleansing Notice

17-Sep-2019	App 3B Placement Shares and Options to Directors and Mgt

2-Sep-2019	Amplia Therapeutics Provides Manufacturing Update

30-Aug-2019	Results of Annual General Meeting

21-Aug-2019	Change of Director's Interest - S Wilkinson - Options Lapsed

12-Aug-2019	Amplia Therapeutics - Quarterly Update

5-Aug-2019	Change of Director's Interest - Dr Warwick Tong Rights Issue

5-Aug-2019	Change of Director's Interest - Dr Chris Burns, Rights Issue

5-Aug-2019	Change of Director's Interest - Andrew Cooke, Rights Issue

31-Jul-2019	Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr

31-Jul-2019	RightsIssue Participation Supports Clinical-Enabling Studies

25-Jul-2019	Amplia Therapeutics - Bioshares Presentation July 2019

25-Jul-2019	Appendix 4G - Key to Corporate Governance Disclosures

25-Jul-2019	2019 Corporate Governance Statement

25-Jul-2019	Notice of Annual General Meeting/Proxy Form

25-Jul-2019	Annual Report to Shareholders - YE 31 March 2019

23-Jul-2019	Amplia Therapeutics Reports Lead Candidate Preclinical Data

22-Jul-2019	Amplia to present to Bioshares Biotech Summit

9-Jul-2019	Update - July 2019 Newsletter

1-Jul-2019	Letter to Shareholders - Rights Issue

28-Jun-2019	Appendix 3B - Rights Issue

28-Jun-2019	Rights Issue Prospectus

27-Jun-2019	Financial Report Year Ended 31 March 2019

24-Jun-2019	Dr John Lambert appointed as new CEO

17-Jun-2019	Preliminary Rights Issue Details

14-Jun-2019	Placement Cleansing Notice

14-Jun-2019	Appendix 3B - Placement $360k

12-Jun-2019	Capital Raising for Clinical-Enabling Studies

29-May-2019	Preliminary Final Report - Year Ended 31 March 2019

30-Apr-2019	Appendix 4C - Quarterly Statement of Cash Flows

1-Apr-2019	European Patent Completes IP Protection in Major Markets

11-Mar-2019	Amplia Expands Advisory Board

12-Feb-2019	Update - February 2019 Newsletter

29-Nov-2018	App 4D Half Year Accounts 30 Sep 2018

13-Nov-2018	Change of Director's Interest - Wilkinson - Options Expired

7-Nov-2018	Change of Director's Interest Notice - Andrew Cooke

30-Oct-2018	Appendix 4C - quarterly

5-Sep-2018	Amplia Investor Introduction

5-Sep-2018	Change of Name to Amplia Therapeutics Limited - ATX

4-Sep-2018	Change of Director's Interest - Cooke - Options

4-Sep-2018	Change of Director's Interest - Peach - Options

4-Sep-2018	Change of Director's Interest - Wilkinson - Options

4-Sep-2018	Appendix 3B - Options

ASX Announcements

Quick Links

Contact Us

Email Alerts